Qsemble Capital Management, LP Cytokinetics Inc Transaction History
Qsemble Capital Management, LP
- $751 Billion
- Q4 2024
A detailed history of Qsemble Capital Management, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Qsemble Capital Management, LP holds 5,545 shares of CYTK stock, worth $234,054. This represents 0.03% of its overall portfolio holdings.
Number of Shares
5,545Holding current value
$234,054% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
409Shares Held
125MCall Options Held
4.55MPut Options Held
2.42M-
Black Rock Inc. New York, NY14.7MShares$619 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$503 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$409 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$328 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$273 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.97B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...